Friday Aug 29
Belviq Sales Crack Critical Level
Sales of the anti-obesity Drug Belviq from Arena Pharmaceuticals passed a critical level today with an improvement of 3.4% over the numbers last week.
Mon Aug 25, 2014
Belviq Sales Rise 2%
Sales of the anti-obesity pill Belviq from Arena Pharmaceuticals continued to buck the seasonality factor by bringing in a 2% increase in week over week sales according to industry tracker IMS Health.
Biotech Hiring Surge: Trends To Watch; Industry Tips from Arena Pharmaceuticals, Inc.
August 25, 2014 By Josh Baxt , BioSpace.com Exclusive Story Everyone remembers the bad old days of 2009.
Fri Aug 15, 2014
FDA Data: Good News For One Anti-Obesity Company, Not So Good For Another
The FDA Adverse Events raw data for Q4 of 2013 have been released, and while the exact information relating to the nature of adverse events will take some time to make its way to the public, it is possible to search through the raw data to see the number of times that a particular drug comes up within the data.
Wed Aug 13, 2014
A Deeper Look At MannKind - Sanofi Deal And Valuation
The excitement of the new deal between MannKind and Sanofi has now been absorbed, and the street is now assessing how it feels the deal will impact MannKind.
Arena Pharmaceuticals Short Interest Down 2.2% in July
Shares of Arena Pharmaceuticals were the recipient of a significant decrease in short interest during the month of July.
Mon Aug 11, 2014
Post-Earnings Review and Highlights - Arena Pharma
Investor-Edge.com has issued complimentary earnings coverage on Arena Pharmaceuticals Inc. as the company featured in the headlines on, per diluted share decline in net income per share in the second quarter of 2014.
Fri Aug 08, 2014
Arena's Belviq Bucks Seasonality With 3.6% Week Over Week Gain
Sales of the anti-obesity pill Belviq from Arena Pharmaceuticals continue to buck the seasonality of the weight loss sector with a 3.6% week over week gain.
Thu Aug 07, 2014
Arena Pharmaceuticals Receives Consensus Rating of "Hold" from Brokerages
Shares of Arena Pharmaceuticals have earned a consensus rating of "Hold" from the eight ratings firms that are currently covering the stock, Analyst Ratings News reports .
Mon Aug 04, 2014
One-Time Stock Sale Boosts Arena To Profit
Arena Pharmaceuticals beat the street by an impressive $0.14 per share. Some investors were thrilled with the news, but more experienced investors saw the quarter for what it was and removed the one-time event to look at this quarter from a business perspective.